Slide 1: Exhibit 99.2
NASDAQ: STXS Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation, the Company may make projections and other forward- looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth op
Slide 3: Investment Considerations
Investment Considerations Addressing market opportunity through two distinct platforms: Magnetic Navigation (Niobe) Enterprise Solutions (Odyssey) Large, high growth (+20%) cardiology ablation market Commercial ramp began in mid 2008; leading peer group grower in 2009 through strong fundamentals Poi
Slide 4: Stereotaxis Magnetic Platform
Stereotaxis – Magnetic Platform Stereotaxis steers the catheter’s distal tip through external magnetic fields thus giving the physician precise remote control of therapeutic devices.
Slide 5: Value of Magnetic Platform
Stereotaxis Value – Magnetic Platform Precise control of the distal tip of the catheter results in: Exemplary safety Effective lesion creation through constant contact Exceptional mapping capability Proven in all chambers of the heart
Slide 6: Before Stereotaxis / After Stereotaxis
Before Stereotaxis After Stereotaxis Physician Efficacy Safety Efficiency In procedure room Physician: significant X-ray exposure Patient: major event rate ~2.8% Wide standard deviation based on patient and physician In control room Several applications clearly better than manual - VT, pediatrics, c
Slide 7: Global EP Market
Global EP Market Source: Millennium Research Group (2009); Stereotaxis internal analysis EP Procedures Routine AF VT Other Total Complex Prevalence Annual Procedures Annual Growth +20M +10M +3M +5M +18M 170k 100k 30k 40k 170k <10% 25% 15% 15% 20% Our Focus
Slide 8: Strong Clinical Validation
Strong Clinical Validation More than 150 Peer-Reviewed Publications Atrial Fibrillation 30 Publications Up to 100% acute success Improved chronic outcomes Pediatric Arrhythmia 5 publications 93% acute success Low fluoro, no complications Congenital Heart 6 publications 90% success rate “As easy as n
Slide 9: Comparison Study Erasmus MC
VT Comparison Study Erasmus MC • 64 consecutive VT ablation patients – 37 Stereotaxis – 27 manual – Idiopathic & Scar-Related • No complications in Stereotaxis group • 1 tamponade/death in manual group • Conclusion: “Major clinical & cost advantages for VT ablation” 97% 14% 81% 50% Acute Success (%)
Slide 10: Odyssey Enterprise Solutions
Odyssey Enterprise TM Solutions Odyssey Vision
Slide 11: The Odyssey Product Line
The Odyssey Product Line CONNECT CINEMA VISION Efficiently integrate data and control during procedures Standardize all labs to increase staff effectiveness Drive world-class practices by capturing, compressing and recording data for storage and networking NIOBE Accelerate clinical education by play
Slide 12: Business Model
Business Model Capital Revenue Recurring Revenue Niobe Odyssey Workstation Odyssey Cinema • 141 Niobe systems installed • 2,500 EP labs worldwide • 20+% growth; ~60% margin • 25% growth (YTD 2010 vs. 2009) • 80% margin Equipment service • Technical service • Software license • 1-year warranty Niobe
Slide 13: Market Adoption & Procedure Growth
Market Adoption & Procedure Growth Growing Worldwide Penetration 141 Systems Installed 60% US - 40% OUS Canada - United States - Europe - Saudi Arabia - Russia - China - Korea - Japan - Singapore - Taiwan - Australia -
Slide 14: Financial Update
$0.0 $4.0 $8.0 $12.0 $16.0 Q1 Q2 Q3 Q4 $11.2 $8.8 $7.2 $7.3 $5.0 $10.2 $12.4 $6.3 $11.2 $7.7 New Orders to Backlog Revenue Momentum Recurring Revenue $ millions $ millions $0 $2 $4 $6 $8 $10 $12 $14 $16 Q1 Q2 Q3 Q4 $7.0 $11.1 $10.6 $10.7 $12.6 $15.0 $10.6 $13.3 $12.1 $14.1 $ millions Stereotaxis Fin
Slide 15: Financial Update
$0.0 $4.0 $8.0 $12.0 Q1 Q2 Q3 Q4 Total Inventory -$20.0 -$15.0 -$10.0 -$5.0 $0.0 $5.0 Q1 Q2 Q3 Q4 Cash Flow (Burn) $0.0 $5.0 $10.0 $15.0 $20.0 $25.0 Q1 Q2 Q3 Q4 Operating Expenses 55.0% 60.0% 65.0% 70.0% 75.0% Q1 Q2 Q3 Q4 Gross Margin Percentage $ millions $ millions $ millions 65.5% 68.9% 72.5% 60.
Slide 16: Liquidity
$3.0 $1.3 $3.6 $6.6 $12.8 $4.3 $22.0 Liquidity $0 $2 $4 $6 $8 $10 Operating Cash Flow Ex A/R BWI Debt Accounts Receivable Q2 2010 Cash Burn Analysis $ Millions $7.9 $ Millions $26.3 $19.4 * Cash burn includes repayment of Biosense Webster advance. * $30.3 $23.8 $20.7 $0 $5 $10 $15 $20 $25 $30 $35 Ca
Slide 17: Focus
Focus I. Drive Commercial Success Clinical training/process accelerates adoption Adoption creates stronger reference sites Reference sites accelerate capital pipeline & sales Niobe orders generate Odyssey opportunities Odyssey (robotic labs) placements generate standard lab interest II.Strengthen EP
Slide 18: Q & A
Q & A